Advanced Therapies Europe

JOIN US!

Complete the form to schedule a meeting with Catalent cell & gene therapy experts at the Advanced Therapies Europe conference!

FEATURED SPEAKING SESSION

Title: Accelerating Pathways from iPSC Lines to Patient Cure: Challenges, Solutions and the Value of Strategic Partnerships

Date: Wednesday, September 11, 2024

Time: 12:45 – 1:45 PM CET

In the iPSC derived Cell Therapy world, developing a suitable iPSC line is a key step, but not the only one. Accessing a GMP iPSC line for clinical and commercial use, gene editing methods, securing efficient differentiation and/or expansion protocols, bringing them to scale and ensuring GMP manufacturing from early clinic to late stage, including optimal analytical testing and patent coverage, are all key steps a biotech will need to cross.

The objective of this workshop is to discuss the challenges faced and solutions found by companies developing iPSC derived Cell Therapies, and the path our panelists have developed to reach their goals. We will also explore how global partnerships can accelerate the journey from innovation to a patient cure.

FEATURED SPEAKERS

ABOUT CATALENT CELL & GENE THERAPY

Catalent Cell & Gene Therapy is an industry-leading technology, development, and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies and viral vectors, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, and oncolytic viruses. An experienced and innovative partner, Catalent Cell & Gene Therapy has a global network of dedicated development, clinical and commercial manufacturing facilities for small- and large-scale programs.